Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Inozyme Pharma, Inc. INZY NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
33/100
0/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$4.00
+0%

Inozyme Pharma, Inc. (INZY) is a Biotechnology company in the Healthcare sector, currently trading at $4.00. It has a SharesGrow Score of 32/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Analyst consensus target is INZY = $4 (+0% upside).

Net income is $102M (loss), growing at -22.7%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $47M against $58M equity (Debt-to-Equity (D/E) ratio 0.81, moderate). Current ratio is 3.56 (strong liquidity). Debt-to-assets is 38.1%. Total assets: $123M.

Analyst outlook: 6 / 9 analysts rate INZY as buy (67%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 50/100 (Partial), Growth 15/100 (Fail), Past 0/100 (Fail), Health 50/100 (Partial), Moat 28/100 (Fail), Future 55/100 (Partial), Income ?/100 (Fail).

$4.00
▲ 0% Upside
Average Price Target
The 12-month price target for Inozyme Pharma, Inc. is $4.00.

INZY SharesGrow Score Overview

40/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 50/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 55/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — INZY

~
VALUE Partial
50/100
INZY trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $4, implying +0% from the current price $4. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
INZY: +0%/yr revenue is, -22.7%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
50/100
Balance sheet INZY: Debt-to-Equity (D/E) ratio 0.81 (moderate), Current ratio is 3.56 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
INZY: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
55/100
Analyst outlook: 6 / 9 analysts rate INZY as buy (67%). Analyst consensus target is $4 (+0% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.721-6.24
Volume1.46M
Avg Volume (30D)2.26M
Market Cap$258.25M
Beta (1Y)2.29
Share Statistics
EPS (TTM)-1.62
Shares Outstanding$62.81M
IPO Date2020-07-24
Employees67
CEODouglas A. Treco
Financial Highlights & Ratios
EBITDA$-104.03M
Net Income$-102.02M
Operating Income$-104.03M
Total Cash$113.09M
Total Debt$46.87M
Net Debt$25.79M
Total Assets$123.18M
Price / Earnings (P/E)-2.5
Analyst Forecast
1Y Price Target$4.00
Target High$4.00
Target Low$4.00
Upside0.0%
Rating ConsensusBuy
Analysts Covering9
Buy 67% Hold 33% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS45790W1080

Price Chart

Track all markets on TradingView
INZY
Inozyme Pharma, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
0.72 52WK RANGE 6.24

People Also View

TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 AMLX
AMLX
Amylyx Pharmaceuticals, Inc.
$16.92
+2.73%
 ELDN
ELDN
Eledon Pharmaceuticals, Inc.
$3.20
-0.62%
 ABOS
ABOS
Acumen Pharmaceuticals, Inc.
$2.68
+6.77%
 PDSB
PDSB
PDS Biotechnology Corporation
$1.06
-2.75%
 MREO
MREO
Mereo BioPharma Group plc
$0.33
+2.81%
 XFOR
XFOR
X4 Pharmaceuticals, Inc.
$4.20
+1.69%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message